

Supplementary Table 1. Baseline demographics and disease characteristics in the IV abatacept trial (1)

Characteristic	4-month, open label lead in period		6-month double-blind period	
	Abatacept (n=190)	Abatacept (n=60)	Abatacept (n=60)	Placebo (n=62)
Age, years	12.4 (3)	12.6 (3)	12.6 (3)	12.0 (3)
Female	137 (72)	43 (72)	43 (72)	45 (73)
Race				
White	147 (77)	46 (77)	46 (77)	49 (79)
Black	15 (8)	5 (8)	5 (8)	4 (7)
Other	28 (15)	9 (15)	9 (15)	9 (15)
Disease duration, years	4.4 (3.8)	3.8(3.7)	3.8(3.7)	3.9 (3.5)
JIA categories				
Polyarthritis RF negative	84 (44)	26 (43)	26 (43)	28 (45)
Polyarthritis RF positive	38 (20)	14 (23)	14 (23)	12 (19)
Extended oligoarthritis	27 (14.0)	9 (15)	9 (15)	7 (11)

Systemic arthritis	37 (20)	11 (18)	12 (19)
Persistent oligoarthritis	3 (2)	0	2 (3)
	n=187 ^a		
Number of active joints	16.2 (12.7)	18.2 (11.5)	14.7 (12.8)
Number of joints with LOM	16.3 (14.5)	17.3 (13.2)	14.3 (13.7)
PGA of disease activity, mm	54.2 (20.3)	53.5 (17.8)	52.7 (21.1)
CHAQ-DI (scale 1-3)	1.3 (0.8)	1.3 (0.7)	1.2 (0.8)
CRP, mg/L	0.32 (0.44)	0.29 (0.46)	0.27 (0.34)
	n=189 ^a		n=61 ^a
Methotrexate dose, mg/m ² /week	13.2 (4.7)	13.5 (4.5)	12.9 (4.0)
	n=140 ^a	n=48 ^a	n=46 ^a

Values are n (%) or mean (SD), unless specified otherwise.

^aNumber of patient data that were available.

REFERENCE

1. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. *Lancet* 2008;372:383–91.